Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy

INTRODUCTION: Passive immunotherapies targeting Aβ continue to be evaluated as Alzheimer’s disease (AD) therapeutics, but there remains debate over the mechanisms by which these immunotherapies work. Besides the amount of preexisting Aβ deposition and the type of deposit (compact or diffuse), there...

Descripción completa

Detalles Bibliográficos
Autores principales: Levites, Yona, Funk, Cory, Wang, Xue, Chakrabarty, Paramita, McFarland, Karen N., Bramblett, Baxter, O’Neal, Veronica, Liu, Xufei, Ladd, Thomas, Robinson, Max, Allen, Mariet, Carrasquillo, Minerva M., Dickson, Dennis, Cruz, Pedro, Ryu, Danny, Li, Hong-Dong, Price, Nathan D., Ertekin-Taner, NIlüfer, Golde, Todd E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103631/
https://www.ncbi.nlm.nih.gov/pubmed/33957936
http://dx.doi.org/10.1186/s13024-021-00453-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103631/
https://www.ncbi.nlm.nih.gov/pubmed/33957936
http://dx.doi.org/10.1186/s13024-021-00453-4

Ejemplares similares